Aileron Therapeutics Inc Company Overview
About Aileron Therapeutics Inc
Aileron Therapeutics (NASDAQ:ALRN) focuses on developing innovative peptide therapeutics designed to provide protection from chemotherapy-induced side effects. Their flagship project, ALRN-6924, is a novel therapeutic aimed at reducing toxicities associated with chemotherapy, enabling cancer patients to tolerate higher doses and longer treatment periods. The company is committed to transforming the experience for cancer patients by allowing them to maintain their quality of life throughout treatment. Aileron's objectives include advancing clinical trials and optimizing application protocols to ensure broad accessibility of their solutions. The company strives to build partnerships and collaborations to accelerate development and reach of their proprietary therapies.
Snapshot
Operations
Products and/or services of Aileron Therapeutics Inc
- ALRN-6924 is a lead project targeting the p53 tumor suppressor protein pathway to treat p53-mutant cancers.
- Focused on developing stapled peptide therapeutics to disrupt protein-protein interactions in cancer therapy.
- Research on combinatory therapies enhancing the efficacy of existing cancer treatments through targeted molecular approaches.
- Efforts in optimizing the delivery mechanisms for peptide-based drugs to improve therapeutic outcomes.
- Developing innovative drug discovery platforms for targeting intracellular receptors and signaling pathways.
- Exploring partnerships and collaborations to expand the applications of their proprietary peptide technology.
Aileron Therapeutics Inc executive team
- Dr. James Brian Windsor Ph.D.CEO, President & Director
- Mr. Timothy M. Cunningham CPA, M.B.A.Interim CFO & Principal Accounting Officer